AI-generated summary
The authors report a prospective study of 20 patients with bilateral intermediate age-related macular degeneration and drusenoid pigment epithelial detachment, comparing laser plus anti-VEGF injections in one eye with the fellow eye as control. Drusen area and detachment height decreased in the laser-treated eyes, and visual acuity improved, with one tear and one angiomatous proliferation in the study cohort. The authors note that longer follow-up is needed.
- Participants
- 20
- Who or what was studied
- Patients with treatment-naive bilateral intermediate age-related macular degeneration featuring drusenoid pigment epithelial detachment, visual acuity 83 letters or less; 20 of 21 enrolled completed 12 months follow-up
- Wavelengths
- 532 nm
- Limits stated in the abstract
- Small sample, a single-arm design with the fellow eye as control, and only 12 months of follow-up, which the authors state is insufficient to establish efficacy and safety.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
This study aims to report the 12 months results of efficacy and safety of laser photocoagulation and anti-vascular endothelial growth factor (VEGF) injections for drusenoid pigment epithelial detachment (dPED). In this prospective study, patients with treatment naïve bilateral intermediate age-related macular degeneration, featuring dPED, with visual acuity ≤ 83 letters were enrolled. The study group received PASCAL laser (532 nm) along the periphery of the dPED, and the fellow eye served as a control group. To prevent complications of choroidal neovascularization, intravitreal anti-VEGF injections to laser treated eye were performed on a 3-month interval up to 1 year. Primary outcomes-drusen area, PED height-and secondary outcomes-best-corrected visual acuity (BCVA), contrast sensitivity, degree of metamorphopsia, NEI-VFQ 25, and fundus autofluorescence-were analyzed. Among 21 patients, a total of 20 patients satisfied the 12 months follow-up. Drusen area and PED height decreased significantly in the laser group, while no significant change appeared in the control group (74.1% vs. - 3.5%, P < 0.001; 76.6% vs. 0.1%, P < 0.001). Mean BCVA improved 4.6 letters in the laser group (vs. 1.1 letters in the control group, P = 0.019). As for safety, one study eye developed retinal pigment epithelial tear, and one control eye developed retinal angiomatous proliferation. Low energy laser photocoagulation and anti-VEGF injection in eyes with dPED showed some improvement in visual acuity. dPED regressed without developing center involving GA in the study eye, but a longer term follow-up is necessary to reveal the efficacy and safety of these treatments. The 2-year results of this study will be followed to reveal long term efficacy and safety of the treatment for dPED.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 532 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Age-related macular degeneration, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.